R 0009/17 of 04.06.2018
- European Case Law Identifier
- ECLI:EP:BA:2018:R000917.20180604
- Date of decision
- 4 June 2018
- Case number
- R 0009/17
- Petition for review of
- -
- Application number
- 00922102.9
- IPC class
- C07D 213/81A61K 31/426C07D 213/82C07D 239/42C07D 417/12C07D 233/90C07D 409/12C07C 237/40C07D 277/56C07D 231/38C07D 263/48
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen and members (B)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- CYCLIC PROTEIN TYROSINE KINASE INHIBITORS
- Applicant name
- Bristol-Myers Squibb Holdings Ireland
- Opponent name
- Isenbruck Bösl Hörschler LLP
APOTEX INC.
Actavis Group PTC ehf
Generics [UK] Limited - Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112a(2)(c)European Patent Convention R 106
- Keywords
- Admissibility of petition: yes
Right to be heard fundamentially violated: no
Petition for review: clearly unallowable - Catchword
- -
- Citing cases
- -
Order
For these reasons the Enlarged Board of Appeal as composed under Rule 109(2)(a) EPC unanimously decides:
The petition for review is rejected as being clearly unallowable.